These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22932130)

  • 1. Targeted therapy for lung cancer.
    Petrosyan F; Daw H; Haddad A; Spiro T
    Anticancer Drugs; 2012 Nov; 23(10):1016-21. PubMed ID: 22932130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI; Gautschi O
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
    Shi YK
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
    [No Abstract]   [Full Text] [Related]  

  • 6. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM; Rudin CM
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
    J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
    Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A
    Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 10. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
    Laack E; Sauter G; Bokemeyer C
    Lung Cancer; 2010 Sep; 69(3):259-64. PubMed ID: 20646778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted treatment tested as potential cancer cure.
    Hayden EC
    Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
    Heigener DF; Reck M
    Adv Ther; 2011 Feb; 28(2):126-33. PubMed ID: 21181318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Therapy and Imaging Findings.
    Shroff GS; Benveniste MF; de Groot PM; Wu CC; Viswanathan C; Papadimitrakopoulou VA; Truong MT
    J Thorac Imaging; 2017 Sep; 32(5):313-322. PubMed ID: 28832416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy for non-small cell lung cancer.
    Jett JR; Carr LL
    Am J Respir Crit Care Med; 2013 Oct; 188(8):907-12. PubMed ID: 23721055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
    Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
    Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib (xalkori) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2012 Feb; 54(1383):11-2. PubMed ID: 22354221
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
    Pao W; Miller VA
    J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.